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ABSTRACT
Antiretroviral therapy (ART) has reduced morbidity and mortality related to human immunodefi -
ciency virus (HIV) infection, but in spite of this advance, HIV mutations decrease antiretroviral sus-
ceptibility, thus contributing to treatment failure in patients. Genotyping HIV-1 allows the selection 
of new drugs after initial drug failure. This study evaluated the genotypic profi le of HIV-1 isolates 
from treated (drug-experienced) patients in Paraná, Brazil. The prevalence of mutations in reverse 
transcriptase (RT) and protease (PR) genes were assessed. We analyzed 467 genotypes of patients 
with HIV-1 viral loads above 1,000 copies/mL. Mutations at HIV-1 RT and PR genes and previously 
used ART regimens were recorded. The most prevalent RT mutations were: 184V (68.31%), 215YF 
(51.6%), 103NS (46%), 41L (39.4%), 67N (38.54%), 210W (23.5%), 190ASE (23.2%), and 181C 
(17.4%). PR mutations were 90M (33.33%), 82ATFS (29%), 46I (26.8%) and 54V (22.2%). The 
prevalence of mutations was in line with previous national and international reports, except to non-
nucleoside analogue reverse transcriptase inhibitors related mutations, which were more prevalent 
in this study. Previous exposure to antiretroviral drugs was associated with genotypic resistance to 
specifi c drugs, leading to treatment failure in HIV patients.
Keywords: HIV-1, genotype, antiretrovirals, drug-experienced patients.
[Braz J Infect Dis 2010;14(4):360-371]©Elsevier Editora Ltda.
INTRODUCTION
Since the last decade, antiretroviral therapy 
(ART) has been altering the course of human 
immunodeficiency virus (HIV) infection in 
Brazil, with dramatic decrease in mortality 
and morbidity. HIV emerged as a potential-
ly treatable chronic infection.1,2 In Brazil, in 
2008, the estimated number of patients on 
combination of antiretroviral (ARV) class-
es, the so-called highly active antiretroviral 
therapy (HAART), was 185,000.2
Some factors, like poor compliance (re-
lated to toxicity or complexity of regimens), 
prescription of suboptimal treatments and 
the “genetic barrier” of some regimen pro-
mote a non-suppressive ART, which strong-
ly contributes to the selection of resistant 
HIV-1 mutants.3 High and continuous rep-
lication rate of HIV-1 in vivo, in addition to 
the error-prone nature of the viral enzymes, 
in the setting of inadequate levels of ARVs, 
lead to marked genetic variation with viral 
mutations that confer drug resistance.4,5
Development of drug resistance is one of 
the most serious obstacles to sustained sup-
pression of HIV and, eventually, multidrug 
resistance can exhaust the patient’s therapeu-
tic options. This population with rising lev-
els of plasma HIV RNA represents potential 
transmitters of HIV, including drug-resistant 
strains, to susceptible people.3,6-8
Since the fi rst report of zidovudine resistance 
in clinical isolates from treated patients in 1989,9,10 
data on prevalence of resistance have been pub-
lished in different geographic areas. Genotyping 
HIV-1 allows for mutations detection in HIV 
genome, particularly at the protease (PR) and re-
verse transcriptase (RT) genes. Based on a large 
knowledge accumulated and published by many 
authors about PR and RT mutations in the last 10 
years, genotype report helps to target selection of 
new drugs after initial drug failure.11-13
Internationally, reports estimating the prev-
alence of antiretroviral resistance have shown 
epidemiological features of the global burden 
of resistance through the years.14-19
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National epidemiological studies have also been 
reviewed. In 2002, Tanuri et al. published data from a 
Brazilian database.20 From 2004 to 2007, many other au-
thors showed data from the prevalence of antiretroviral 
resistance in adults from Bahia, São Paulo, Rio de Ja-
neiro, Federal District and North Eastern states.21-27
The aim of this study is to analyze the genotypic pro-
file of patients tested for resistance in the Brazilian state 
of Paraná, in order to determine the frequency of RT 
and PR mutations among patients failing ART.
MATERIAL AND METHODS
This study was approved by the Ethics Committee of 
Hospital de Clínicas of Federal University of Paraná 
(UFPR) and by the Laboratory Division of Brazilian 
AIDS Programme (PN-DST/AIDS) of Brazilian Minis-
try of Health (MH).
Study population and antiretroviral therapy
Adults on ARV treatment failure in Paraná, Brazil, with 
genotyping tests from 2002 to 2006 were selected. Geno-
types were obtained as part of routine clinical care and 
indicated when a patient on ART presented virologic 
failure. The sources were genotypes from private pa-
tients and local genotype results from the National Gen-
otyping Network (RENAGENO). An informed consent 
was signed by all patients before sample collection.
The observational analysis included patients’ ART 
history, viral load (VL) in every ARV regimen failure, 
CD4 counts (nadir and last available count before geno-
typing), and PR and RT HIV-1 mutations. Therapeutic 
failure was defined as VL higher than 1,000 copies/mL 
after continuous use ART for more than three months. 
Patients whose tests were performed by RENAGENO 
had VL higher than 5,000 copies/mL.
Patients should have been exposed to at least two 
ARV, including: nucleoside analogue reverse tran-
scriptase inhibitors (NRTIs), non-nucleoside analogue 
reverse transcriptase inhibitors (NNRTIs), and protease 
inhibitors (PIs). Patients were excluded when informa-
tion about ART was missing or incomplete.
HAART was defi ned as a combination of at least three 
antiretroviral agents, including two NRTIs and a NNRTI or 
a PI. Some patients used boosted PIs. NRTI mono or dou-
ble therapy were considered non-HAART regimen.
Genotypes description
Genotypings were done by polymerase chain reaction 
(PCR) amplifi cation and DNA sequencing technique. The 
HIV-1 genomic region analyzed was POL, specifi cally the PR 
and RT codons. Genotypic sequencing was performed using 
commercially available assays, with over 70% of samples be-
ing tested with ViroSeq HIV-1 Genotype System®. 
Reports from RENAGENO where performed by ViroSeq 
HIV-1 Genotype System® from Celera Diagnostics (Applied 
Biosystems). Reports of private patients were performed by 
one of the following assays: GenoSure® (by LabCorp), virco-
TYPE HIV-1® (by VIRCO) and GeneSeq® (by Monogram, 
formerly ViroLogic Inc.).
The epidemiology of mutations found was described 
and no Genotype Algorithm was used to interpret re-
sults in this study.
Mutations definition
Mutations associated with reduced antiretroviral drug 
susceptibility are described below and were based 
on the compilation of data reported by the Stanford 
University HIV Drug Resistance Database, updated 
in 2005 and 2008,11,28 and the International AIDS So-
ciety – USA Panel Guidelines reports from 2000 to 
2008.12,29-41
Mutations associated with reduced susceptibility to 
NRTIs are at RT gene positions 41, 43, 44, 62, 65, 67, 
69, 70, 74, 75, 77, 115, 116, 118, 151, 184, 208, 210, 215, 
218, 219, 221, and 228. Thymidine associated muta-
tions (TAMs) are M41L, D67N, K70R, L210W, T215YF, 
K219QE. Accessory mutations include K43EQ, E44AD, 
V118I, H208Y, D218E, H221Y, and L228HR. The non-
thymidine associated mutations are K65R, K70EG, L74V, 
Y115F, M184VI. Additional mutations are related to 
treatment with NRTI with no clear phenotypic signifi-
cance, and include D67GE, T69DSAN, V75AS, K219NR. 
Multi-NRTI resistance mutations that confer resistance 
to all NRTIs are 69 insertion, A62V, V75I, F77L, F116Y, 
Q151M.
NNRTIs-associated mutations included amino acid 
substitutions at RT gene positions A98G, L100I, K101E/P, 
K103N/S, V106A/M/I, V108I, V179D/E/F/T, Y181C/I/V, 
Y188C/H/L, G190A/S, P225H, F227L/C, M230L, and 
K238T.
Major PI mutations included amino acid substitu-
tions at PR gene positions D30N, V32I, L33F, M46I/L, 
I47V/A, G48V/M, I50L/V, I54M/L, Q58E, T74P, V82A/
F/L/T/S, I84V/A/C, N88D/S, and L90M. Minor PI muta-
tions included the substitutions in positions L10F/I/R/V, 
V11I, I13V, G16E, K20M/R/I/T, L23I, L24I, E34Q, E35G, 
M36I/V, K43T, F53L, I54V/T/A/S, D60E, I62V, L63P, 
I64L/M/V, A71V/T/I, G73S/T, L76V, V77I, N83D, I85V, 
L89V, and I93L/M of PR.
Database construction
Collection Data was stored at Access 2007 for Windows 
Vista and exported to Excel 2007 for Windows Vista for 
analyses. There were 393 variables, including every TR 
and PR mutations, data about previous ART, and demo-
graphic data.
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Statistical analysis
Statistical analyses were performed with STATA 8.2 for 
Windows (Statacorp, Texas).
The distribution of categorical variables was compared 
using the Chi square-test. Odds ratio was used to compare 
differences in frequencies. We studied the association be-
tween mutations and sex, as well as changes of mutations 
prevalence throughout the years. 
The association between the presence of mutation and 
previous exposure to certain ARV was assessed by univariate 
and multivariate analyses. Dependent variables were the mu-
tations, and the ARV exposure was the independent variable.
The signifi cance level of 0.05 and a Confi dence Interval 
(CI) of 95% were used.
RESULTS
From more than 600 genotypes performed from 2002 to 
2006, 467 genotypes of 467 patients from Paraná State 
were evaluated. The genotypes of paediatric patients and 
the exams of patients whose ART history could not be 
elucidated were excluded. For patients with more than 
one genotype, the most recent one was included. RE-
NAGENO performed 73.7% of the genotypes (Table 1). 
PR and RT subtype was defined in 389 (83.3%) patients, 
most of them (61.4%) were subtype B, 20.6% subtype C 
and 4.9% were subtype F. About 13.1% of the patients 
showed mixtures in PR and RT subtypes.
Mean age of patients in study was 41.12 ± 9.1 years, and 
most of them (n = 308; 66%) were males. Mean viral load in 
patients with failing regimens – including NRTI, NNRTI, and 
PI – was of 1,000 to 30,000 copies/mL. Most patients (72%) 
had AIDS and 56.7% had mean nadir CD4 count lower than 
150 cells/mL. After ART, 59.6% had CD4 count above 200 and 
31% above 350 cells/mL, in spite of virologic failure.
Patients were exposed to 6.69 ± 2.94 ARVs and 4.03 ± 
2.45 ART combinations. The three ARV classes (NRTI, 
NNRTI, and PI) were used by 296 (63.4%) patients. Sev-
enty three (15.6%), 89 (19.1%) and 9 (1.9%) patients used 
PI plus NRTI, NNRTI plus NRTI and NRTI double therapy, 
respectively. 
NRTI double therapy was the most frequent initial regi-
men (Table 2). From patients starting on two NRTI, 59.16% 
received a PI containing HAART and 36.12% received a 
NNRTI containing HAART as subsequent therapy.
HAART used when genotype was requested included 
lamivudine in 80.94%, a NNRTI in 50.54% and a boosted PI 
in 35.55% (Figure 1).
Mean duration of drug exposure was longer for NRTIs and 
shorter for some PIs, like saquinavir (Table 3).
Table 1. Characterization of the study genotypes by 
date of collection and methodology of performance
  Number (n) Frequency (%)
Date of genotype
 2002 22  4.71
 2003  30  6.42
 2004 117  25.05
 2005 186  39.83
 2006  112  23.98
Genotype assay
 ViroSeq System® - 
 Applied biosystems 344  73.66
 (Renageno)
 VircoTYPE HIV-1® 83  17.77
 (VIRCO)
 GenoSure® (LabCorp) 22  4.71
 GeneSeq® 18  3.85
 (Monogram, ViroLogic)
PR = protease, RT = reverse transcriptase.
Table 2. Patterns of initial and last antiretroviral 
regimen used
  Number (n) Frequency (%)
Initial regimen    
 NRTI + PI 179 38.33
 NRTI + boosted PI 6 1.28
 NRTI + NNRTI 65 13.92
 Monotherapy (AZT) 27 5.78
 NRTI double therapy 191  40.89
Last regimen    
 NRTI + PI 95 20.34
 NRTI + boosted PI 166 35.55
 NRTI + NNRTI 236 50.54
 Monotherapy (AZT) 0 0
 NRTI double therapy 9 1.93
NRTI = nucleoside analogue reverse transcriptase inhibi-
tors, NNRTI = non-nucleoside analogue reverse transcriptase 
inhibitors, PI = protease inhibitors, AZT = zidovudine.
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The wild-type virus was present in 23 (4.9%) patients. Muta-
tions conferring resistance to only one ARV class were seen in 66 
(14.1%) patients. Resistance-mutations to two ARV classes were 
detected in 241 (51.6%) patients, and most of them were resistant 
to NRTI and NNRTI (59.34%), followed by resistance to NRTI 
and PI (38.6%), and to PI and NNRTI (2.1%). Resistance muta-
tions to the three classes was detected in 137 (29.3%) patients.
Any NRTI mutation was present in 405 (86.7%) patients. 
M184V alone was detected in 64 (13.7%) patients. The preva-
lence of NRTI-related mutations is showed in Figures 2 and 3. 
Most patients (88%) were on thymidine analogues at the time of 
genotype and 99.8% of patients were previously exposed to a thy-
midine NRTI, 45% had more than three TAMs, and 21.8% had 
both M41L and L210W mutations, but 32.8% had no TAMs.
NNRTI-related mutations were present in 316 (67.7%) 
patients and the most frequent were K103NS, G190AES, and 
Y181C. The prevalence of NNRTI-related mutations present 
in the group of NNRTI-exposed patients is listed in Figure 4. 
Three out of 73 (4.10%) patients exposed only to PI and NRTI 
presented NNRTI-related mutations: one had K103N muta-
tion, the other patient had Y181C and G190A mutations, and 
the third one presented Y181C, K101E and A98G mutations. 
Major PI mutations were present in 239 (51.2%) patients 
and minor PI mutations were present in 455 (97.4%). The 
Figure 1: Overall antiretroviral regimen use (%) – The dark 
grey columns represent the frequency of patients on each 
ARV at the time of genotype. The light grey columns represent 
the frequency of patients ever exposed to each ARV since the 
beginning of treatment.
Nucleoside analogue reverse transcriptase inhibitors: AZT – 
Zidovudine, d4T – Stavudine, 3TC – Lamivudine, ddI – Didanosine, 
ddC – Zalcitabine, ABC – Abacavir, TDF – Tenofovir.
Non-nucleoside analogue reverse transcriptase inhibitors: EFV – 
Efavirenz, NVP – Nevirapine, DLV – Delavirdine.
Protease Inhibitors: RTV – Ritonavir, SQV – Saquinavir, IDV – 
Indinavir, NFV – Nefinavir, ATV – Atazanavir, APV – Amprenavir, 
SQV/r – Saquinavir/ritonavir, Indinavir/ritonavir (IDV/r), ATV/r 
– Atazanavir/ritonavir, APV/r – Amprenavir/ritonavir, LPV/r – 
Lopinavir/ritonavir, DRV/r – Darunavir/ritonavir.
most frequent major PI mutation was L90M. The prevalence 
of PI-related mutations in the group of patients exposed to 
PI is listed in Figures 5 and 6. Two out of 89 patients (2.3%) 
exposed only to NNRTI e NRTI had major PI-related mu-
tations: one had 30N mutation and the other patient had 
D30N, N88D and L90M mutations. 
Exposure to each ARV class was signifi cantly related to 
the presence of resistance mutations conferring resistance to 
these classes. NNRTI-related mutations occurred more of-
ten after NNRTI exposure (OR 10.57, 95% CI = 4.03-22.73, 
p = 0.000). Likewise, major PI mutations were more frequent 
after PI exposure (OR 4.55, 95% CI = 2.45-8.46, p = 0.000). 
Initial therapy consisting of two NRTIs (double therapy) was 
signifi cantly related to a higher frequency of TAMs (OR 1.69, 
95% CI = 1.12-2.54, p = 0.01) and the higher number of TAMs 
was also more prevalent in the group of patients who was ex-
posed to double therapy (OR 1.16, 95% CI = 1.05-1.28, p = 
0.004). NNRTI based HAART as fi rst therapy was associated 
to lower prevalence of TAMs (OR 0.41, 95% CI = 0.24-0.71, 
p = 0.0009). 
M184IV was related to lamivudine exposure (OR 26.21, 
95% CI = 5.66-121.42, p = 0.0000). After multivariate analy-
sis, TAMs were associated to longer exposure to d4T, and 
patients exposed to ddI and TDF showed signifi cantly more 
Table 3. Mean duration of each antiretroviral exposure
Antiretroviral Mean duration of exposure  
 (months)
Zidovudine 26
Stavudine 23
Lamivudine 40
Didanosine 8.5
Zalcitabine 11
Abacavir 6
Tenofovir 9
Efavirenz 10.5
Nevirapine 10
Delavirdine 3
Ritonavir 8
Saquinavir 2
Indinavir 11
Nelfinavir 11
Atazanavir 10
Amprenavir 6
Saquinavir/ritonavir 8.5
Indinavir/ritonavir 8
Atazanavir/ritonavir 7
Amprenavir/ritonavir 9
Lopinavir/ritonavir 3
Darunavir/ritonavir 10.5
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Figure 2: Prevalence (%) of NRTI-related mutations I – The 
horizontal columns represent the frequency of NRTI-related 
mutations (Thymidine analogue mutations, Accessory and 
Additional mutations) in the 467 patients evaluated. Each 
column is described at the legend on the right. Additional 
mutations are 67G, 69DAN and 75A. Accessory mutations 
are 43EQ, 44AD, 181I, 208Y, 218E, 221Y and 228H. TAMs are 
41L, 67N, 210W, 215FY and 219EQ. There were no 67E, 69S, 
75S and 228H mutations in these patients.
TAMs = thymidine analogue mutations, NRTI = nucleoside 
analogue reverse transcriptase inhibitors.
Figure 3: Prevalence (%) of NRTI-related mutations II – The 
horizontal columns represent the frequency of NRTI-related 
mutations (non-thymidine analogue mutations, and multi-
nrti resistance mutations) in the 467 patients evaluated. 
Each column is described at the legend on the right. Non-
TAMs are 115F, 75M, 75T, 74I, 74V, 65R e 184V. Multi-NRTI 
Resistance Mutations are 62V, 75I, 77L, 116Y and 151M and 
the insertion 69.
TAMs = thymidine analogue mutations, NRTI = nucleoside 
analogue reverse transcriptase inhibitors.
Figure 4: Prevalence (%) of NNRTI-related mutations – The vertical columns represent the frequency of NNRTI-related mutations 
in the 382 patients exposed to NNRTIs. Each column is described at the legend on the right. The mutations 179T, 181IV and 
188H were not present in these patients.
NNRTI = non-nucleoside analogue reverse transcriptase inhibitors.
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Figure 5: Prevalence (%) of Major PI-related mutations – 
The vertical columns represent the frequency of PI-related 
mutations in the 366 patients exposed to PIs. Each column 
is described at the legend on the right (30N, 32I, 33F, 46IL, 
47AV, 48VM, 50LV, 54ML, 58E, 74P, 76V, 82ATFS, 84V, 
88DS, 90M). The mutations 84AC were not present in these 
patients.
PI = protease inhibitor.
Figure 6: Prevalence (%) of Minor PI-related mutations – 
The vertical columns represent the frequency of PI-related 
mutations in the 366 patients exposed to PIs. Each column is 
described at the legend on the right (10FIRV, 11I, 13V, 20MIR, 
23I, 24I, 34Q, 36IV, 43T, 53L, 54VTAS, 60E, 62V, 63P, 71VIT, 
73ST, 77I, 83D, 85V, 89V, 93L). The mutations 16E, 20T, 35G 
e 64LMV were not present in these patients. 
PI = protease inhibitor.
TAMs. Mutations on codons 74, 75 and 115 of RT were as-
sociated to longer exposure to TDF and ddI. On multivari-
ate analysis tenofovir exposure was signifi cantly associated 
to the presence of 74IV (OR 2.67, 95% CI = 1.27-5.63, p = 
0.010) and 115F (OR 1.97, 95% CI = 1.01-53.60, p = 0.048) 
(Table 4). Likewise, the presence of mutations on codons 
103, 101 and 106 was associated to exposure to EFV and 
NVP. Mutations on codons 181, 190 and 227 were signifi -
cantly associated to NVP exposure, and at codons 100, 108, 
179 and 225, to EFV exposure (Table 5).
Exposure to full dose ritonavir was related to the presence 
of 33F, 46IL, 47AV, 48V, 50V, 58E, 76V, 82ATFS, 84V, 90M. Ex-
posure to indinavir was related to 32I, 33F, 46IL, 58E, 74P, 76V, 
82ATFS, 84V, 90M. Exposure to boosted indinavir was related 
to 33F, 46IL, 58E, 54ML, 82ATFS, 90M. Exposure to saquina-
vir was related to 32I, 33F, 48V, 76V, 82ATFS, 84V, 90M. Ex-
posure to boosted saquinavir was related to 33F, 46IL, 48V, 
58E, 82ATFS, 84V, 90M. Exposure to nelfi navir was related to 
30N, 33F, 46IL, 50L, 58E, 88DS, 90M. Exposure to atazana-
vir was related to 50L, 74P, and, to boosted atanavir, to 32I, 
33F, 46IL, 47AV, 54ML, 82ATFS, 90M. Exposure to boosted 
lopinavir was related to 46IL, 47AV, 48VM, 50V, 54ML, 58E, 
76V, 82ATFS, 84V, 90M. Exposure to amprenavir was related 
to 32I, 54ML, 58E, and, to boosted amprenavir, to 33F, 46IL, 
47AV, 50V, 54ML, 58E, 82ATFS, 84V, 90M. Exposure to boost-
ed darunavir was related to 32I, 33F, 47AV, 50V, 54ML, 76V.
After logistic regression analysis, lopinavir/ritonavir ex-
posure was not a risk factor to the presence of G48VM after 
controlling for SQV and SQV/r exposure (OR 8.67, 95% CI = 
0.85-87.98, p = 0.068). SQV exposure was not associated with 
the presence of L76V after controlling for DRV/r and LPV/r 
exposure (OR 3.02, 95% CI = 0.68-13.67, p = 0.146). The pres-
ence of 33I was associated only with the exposure to LPV/r, IDV 
and IDV/R, but not with NFV (OR 1.55, 95% CI = 0.75-3.18, p 
= 0.234) or DRV/r (OR 4.74, 95% CI = 0.40-56.94, p = 0.320).
The presence of major PI mutations, TAMs and other 
NRTI-related mutations was significantly associated with 
the exposure to a higher number of HAART regimens and 
a higher number of ARVs (Table 6).
When the frequency of ARV classes’ exposure was ana-
lyzed, the use of NNRTIs, PIs and exposure to the three ARV 
classes was similar for patients who were genotyped from 
2002 to 2006. There was a signifi cant increase of tenofovir use 
and 3TC at the moment of test, and an overall decrease of ex-
posure to thymidine analogues from 2002 to 2006 (Table 6).
Overall distribution of resistance mutations related to 
the three classes had no signifi cant difference throughout the 
years, except for the signifi cantly higher prevalence of acces-
sory mutations (Figures 7 and 8). Some isolated mutations 
became signifi cantly more prevalent over time (Table 7).
Some TAMs, V118I and PI mutations, like L90M, were 
more frequent in the HIV-1 isolates of male patients (Table 8).
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Table 4. Multivariate analyses to NRTI exposure and presence of TAMs
Mutation ARV exposure  OR* 95% IC p-value
TAMs Exposure to AZT 0.99 0.44-2.28 0.999
 Longer AZT exposure 1.16 1.00-1.34 0.051
 Exposure to d4T 1.02 0.65-1.61 0.926
  Longer d4T exposure 1.25 1.09-1.43 0.001
  Exposure to TDF 3.36 1.39-8.15 0.003
  Exposure to ddI 1.85 1.23-2.78 0.007
74IV Longer ddI exposure 1.42 1.12-1.78 0.0031
  Longer TDF exposure 2.71 1.54-4.77 0.0005
75TM Longer ddI exposure 1.42 1.05-1.90 0.0214
  Longer TDF exposure 2.73 1.33-5.62 0.0064
115F Longer ddI exposure 2.64 1.22-5.74 0.0141
  Longer TDF exposure 9.04 1.36-59.89 0.0225
TAMs = thymidine analogue mutations, NRTI = nucleoside analogue reverse transcriptase inhibitors, AZT = zidovudine, 
d4T = stavudine, TDF = tenofovir, ddI = didanosine.
OR = odds ratio, CI = confidence interval.
*Odds ratio for the occurrence or not of mutations when patients were exposed to these ARVs..
Table 5. Multivariate analyses to NNRTI exposure and presence of NNRTI related mutations
Mutation ARV exposure OR* 95% IC p-value
100I  12.05 2.50-58.17 0.0001
108I Exposure to EFV 2.11 1.00-4.53 0.0484
179DEF  9.18 1.16-72.92 0.0107
225H  10.97 3.86-31.19 0.0000
181C  9.92 4.58-21.49 0.0000
190ASE Exposure to NVP 4.26 2.50-7.29 0.0000
227L  3.87 1.04-14.37 0.0291   
101EPH  2.04 1.02-4.06 0.0383
  2.30 1.13-4.67 0.0178
103NS Exposure to EFV and NVP 3.92 2.52-6.09 0.0000
  4.28 1.17-15.70 0.0168
106AM  8.31 1.04-66.47 0.0168
   3.46 1.47-8.17 0.0025
NNRTI = non-nucleoside analogue reverse transcriptase inhibitors, EFV = efavirenz, NVP = nevirapine.
OR = odds ratio, CI = confidence interval.
*Odds ratio for the occurrence or not of mutations when patients were exposed to these ARVs.
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Table 6. Amount of ARV exposure and presence of mutations
Mutation ARVs and regimens OR* 95% CI p-value
TAMs Increasing number of HAART regimen 1.11 1.03-1.20 0.0082
TAMs-Accessory mutations  1.11 1.02-1.20 0.0094
Multi-NRTI resistance mutations  1.15 1.02-1.30 0.0247
NNRTI mutations  1.09 1.01-1.18 0.0301
Major PI mutations  1.28 1.19-1.37 0.0000
TAMs Increasing number of ARV exposure 1.08 1.01-1.15 0.0214
TAMs-Accessory mutations  1.10 1.02-1.17 0.0056
NRTI-Additional mutations  1.14 1.05-1.24 0.0017
Multi-NRTI resistance mutations  1.13 1.02-1.25 0.0208
Major PI mutations  1.26 1.18-1.34 0.0000
ARV = antiretroviral, TAMs = thymidine analogue mutations, HAART = highly active antiretroviral therapy, NRTI = nucleoside ana-
logue reverse transcriptase inhibitors, NNRTI = non-nucleoside analogue reverse transcriptase inhibitors, PI = protease inhibitors
OR = odds ratio, CI = confidence interval.
*Odds ratio for the occurrence or not of mutations when patients were exposed to an increasing number of ARVs and therapeutic 
regimens.
Table 7. Evidence of changes on ARV exposure, and PR and TR mutations from 2002 to 2006
   OR* 95% CI p-value
ARV exposure  
 On lamivudine  1.43 1.14-1.78 0.0016
 On tenofovir 1.94 1.46-2.57 0.0000
 Exposure to tymidine analogues 0.72 0.55-0.94 0.0159
NRTI-related mutations  
 M184V  1.25 1.04-1.50 0.0200
 L210W 1.28 1.04-1.57 0.0172
 K43EQ 1.45 1.08-1.95 0.0127
 L228H 1.44 1.09-1.91 0.0094
NNRTI-related mutations  
 V108I 1.44 1.03-1.99 0.0313
 M230L 2.40  1.11-5.19 0.0256
PI-related mutations  
 M46IL 1.33 1.09-1.63 0.0055
 I47AV 2.01 1.19-3.40 0.0095
 Q58E 1.59 1.08-2.34 0.0183
 I54ML 1.61 1.03-2.53 0.0376
 T74P 2.18 1.16-4.09 0.0155
ARV = antiretroviral, NRTI = nucleoside analogue reverse transcriptase inhibitors, NNRTI = non-nucleoside analogue reverse 
transcriptase inhibitors, PI = protease inhibitors.
OR = odds ratio, CI= confidence interval.
*Odds ratio for the occurrence or not of mutations when patients were evaluated from 2002 to 2006. This represents an in-
crease of mutations and ARV exposure.
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DISCUSSION
This study aimed to estimate HIV drug resistance in patients 
receiving ART in Paraná, Brazil, from 2002 to 2006. This fi rst 
estimate of the prevalence of mutations in our region shows 
a high frequency of resistance, similar to other Brazilian sites 
but higher for some patterns of mutations.
Almost all patients were exposed to thymidine NRTIs 
and lamivudine. Double therapy was the initial regimen in 
more than one third of patients. These features explain the 
high number of NRTI related mutations.
About half of patients were exposed to NNRTIs and 
most of them presented NNRTI related mutations. The PI 
used by most patients was nelfi navir followed by unboosted 
indinavir, representing the pattern of drug usage in the 90’s, 
when most of these patients started therapy.
The increasing exposure to tenofovir was signifi cant and 
reﬂ ects the availability of this drug after 2002 in clinical tri-
als and in 2004 delivered by the PN-DST/AIDS.
About 15% of patients were exposed to boosted and un-
boosted atazanavir and 30% to boosted lopinavir, the most 
used PI nowadays, also reﬂ ecting the time of inclusion of 
Table 8. Prevalence of mutations according to gender 
Mutation  Male sex (n = 308)  Female sex (n=159) OR 95% IC p-value
   Number (n)  Frequency (%) Number (n)  Frequency (%)      
M41L 138  44.8 46  28.9 1.99 1.32-3.02 0.0009
D67N 135  43.8 45  28.3 1.98 1.30-3.00 0.0011
L210W 88  28.6 22  13.8 2.49 1.41-4.20 0.0004
T215Y 118  38.3 41  25.8 1.79 1.17-2.74 0.0069
> 3 TAMs 160  51.9 50  31.4 1.26 1.13-1.40 0.0000
V118I 76  24.7 25  15.7 1.76 1.06-2.90 0.0261
M46I 72  23.4 16  18.2 2.73 1.51-4.91 0.0005
V82A 64  20.8 19  11.9 1.93 1.11-3.37 0.0181
L90M 93  30.2 31  19.5 1.79 1.12-2.84 0.0132
I54V  66  21.4 16  10.1 2.4 1.35-4.40 0.002
L24I  17  5.5 2  1.3 4.59 1.04-20.29 0.0273
TAMs = thymidine analogue mutations, OR = odds ratio, CI = confidence interval
Figure 7: Evolution of prevalence of mutations over the 
years – The graphic represents the frequency of patients 
with wild-type virus, and with each class mutation pattern. 
These frequencies were stratified in the genotype samples 
from 2002, 2003, 2004, 2005, and 2006.
NRTI = nucleoside analogue reverse transcriptase inhibitors, 
NNRTI = non nucleoside analogue reverse transcriptase 
inhibitors, PI = protease inhibitor.
Figure 8: Evolution of NRTI-related mutations over the years – 
The graphic represents the frequency of patients with NRTI-
related mutations. These frequencies were stratified in the 
genotype samples from 2002, 2003, 2004, 2005, and 2006.
All mutations had the same prevalence pattern over the years 
except the Accessory mutations and the M184V, which have 
increased from 2002 to 2006. * (OR 1.25, 95% CI = 1.04-1.50, 
p = 0.02), ** (OR 1.23, 95% CI = 1.02-1.47, p = 0.0277).
TAMs = thymidine analogue mutations, NRTI = nucleoside 
analogue reverse transcriptase inhibitors , OR = odds ratio, 
CI = confidence interval.
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these drugs in the PN-DST/AIDS during the study period. 
Less than 1% of patients were exposed to darunavir, PI avail-
able since 2004 in clinical trials.
The most frequent mutations in RT were associated to 
lamivudine and NNRTIs exposure, which confi rms the low 
genetic barrier of these drugs.42
Due to high prevalence of exposure to thymidine ana-
logues and the presence of TAMs, K65R is expected to occur 
in a very low prevalence, as in the presence of multiple TAMs 
K65R is rarely selected on the same human immunodefi -
ciency virus type 1 genome in vivo.43
In this study, the prevalence of mutations was signifi -
cantly higher in the group of patients exposed to more drugs 
and more regimens. This was the case for TAMs, NRTI ac-
cessory mutations, NNRTI related mutations and major PI 
mutations. Initial double therapy was also signifi cantly as-
sociated to more TAMs.
Patients starting HAART with a regimen including 
NNRTI presented less TAMs, probably because, besides 
avoiding double therapy, the tolerability of this regimens 
promoted better adherence. The same was not seen in the 
group starting HAART with a regimen including unboosted 
PIs, frequently a less tolerable regimen. Additionally, patients 
starting with unboosted PIs were exposed to higher number 
of drugs (6.99 versus 4.75) and regimens (3.75 versus 2.29) 
than patients starting with NNRTIs.
The low prevalence (less than 5%) of mutations associ-
ated with classes not previously used may represent primary 
resistance, acquired resistance or a false positive result. For 
patients exposed only to NNRTI and NRTI presenting ma-
jor PI mutations, primary resistance is a possibility, since PI 
where fi rst available to treatment for this group of patients 
tested in the early 2000’s.
The association between exposure to thymidine ana-
logues and higher number of TAMs was not neither sig-
nifi cant in univariates or multivariate analyses as almost all 
patients were exposed to these drugs, but the longer time of 
exposure (specially to d4T) was signifi cantly associated to 
more TAMs. Tenofovir and ddI exposure were signifi cantly 
associated to higher number of TAMs not as a causal rela-
tionship, but because patients with exposure to more regi-
mens had more TAMs and consequently were exposed to 
tenofovir and ddI since 2004.
Almost 5% of patients had no mutations in RT and PR, 
similarly to other Brazilian reports, where the prevalence of 
wild-type virus was less than 10% of samples.21,23,25,26 Only 
one national study showed even higher prevalence of wild-
type virus (15.3%).20
The most prevalent mutation occurred at codon 184 
(68.31%), as reported in São Paulo (64%),24 Rio de Janeiro 
(67%),23 and Northeast Brazil (66%).25 In Santos, from 2006, 
this mutation was even more prevalent (88%).27 In Paraná, 
when samples from 2006 were analysed, the prevalence of 
M184V was of 75%, consistent with the signifi cant increase 
of lamivudine exposure.
The frequency of mutations was high for all classes of 
antiretrovirals, which was expected for patients who had 
already been on different antiretroviral regimens. Predomi-
nantly, primary mutations were associated with NRTIs and 
NNRTIs. The high prevalence of TAMs (67.24%) was simi-
lar to that reported in São Paulo (73%).24
The K65R mutation was not reported in most national 
studies and has occurred in less than 1% of the patients in 
this study. At Brazilian Northeast region this mutation was 
seen in 3.4% of patients and, specifi cally in the state of Ceará, 
in 5.9% of cases.23,26
The overall prevalence of NNRTI mutations (67.7%) 
was higher than in other Brazilian series, probably because 
recently described NNRTI mutations (codons 101, 106, 
179) were included in the analysis. Most of other Brazilian 
studies reported NNRTI prevalence of mutations of 30 to 
55.4%.21,23,25,26 In Santos, the overall NNRTI prevalence was 
not explicit, but K103N occurred in 52% of patients, where-
as in these data from Paraná it was 43.4%.27 At Brazilian 
Northeast region, the specifi c mutations were even higher, 
with 62% substitutions in codon 103, 38.7% in codon 190 
and 181 in codon 29.2%.25 At Rio de Janeiro, K103N was 
seen in 27.7%, but the the frequency of other mutations was 
similar to what was observed in Paraná: G190S/A in 22.12%, 
and Y181C/I in 17.4%.23
The PI related mutations were comparable to many 
other series. Mutation at codon 90 was the most frequent, 
followed by codons 46 and 82, prevalences similar to 25.5, 
23.7 and 21.1%, respectively reported by Cavalcanti et al. 
(2005).23 In the other Brazilian studies, L90M was also the 
most frequent, present in 26 to 37% of the cases.20,21,23,24,44
Compared with international data, these patients present 
lower prevalence of wild-type virus, probably because in 
other sites – where genotype was available earlier in the 
setting of virologic failure – more wild-type virus can be 
demonstrated. Other reason may be the lower exposure to 
less effective regimens, including less than two active agents. 
The prevalence of wild-type virus ranged from 14 to 22% in 
many trials.14,16,17,45,46
The pattern of PI and NRTI resistance mutations in 
Paraná was similar to some international series. PI resistance 
mutations occurred in 41 to 53% and NRTI related muta-
tions occurred in 71 to 80% of samples from Spain, France, 
Italy and USA.14,17,45-48
Data from other countries showed lower prevalence (25 
to 52%) of NNRTI mutations than this study.14,15,17,45-48
The most prevalent mutations worldwide were at co-
dons 184 and 103 of TR, and 90 of PR, but they were less 
frequently than in this sample. M184V/I, K103N and L90M 
occurred respectively in 49.27 and 31% of patients in Spain 
and in 58.31 e 31% of patients in France.44,48 Napravnik 
Toledo, Carvalho, Romagnoli et al.
370
et al. (2007) reported 79, 58 and 59% of M184V/I, K103N 
and L90M mutations respectively, but the analysis included 
only patients with three-class resistance, which explains this 
high prevalence.19 Rhee et al. (2004) reported K65R in 1.9% 
of patients and Costagliola et al. (2007) reported it in 5% of 
cases.16,49
The prevalence of mutations conferring resistance to the 
three ARV classes was similar and even higher than other na-
tional and international studies in which it has been shown 
to be about 17 to 21%.25,46-48
No decrease in the prevalence of mutations has been ob-
served in the sample from Paraná over the years, but some 
European studies did show an overall decrease in prevalence 
of TR and PR mutations, reﬂ ecting a better response to 
HAART.40-52
Differences in gender related prevalence are not widely 
described, but Di Giambenedetto et al. (2007), according to 
data from some mutations in Paraná, considered male sex 
an independent predictor of drug resistance.50
In terms of NNRTIs as future treatment options for this 
group of patients, it has been found that mutations on RT 
codons 181 and 190 occurred in more than 20% of patients, 
which could compromise etravirine effi cacy if used in a 
suboptimal regimen. The new PI darunavir is an important 
future option to this group, as mutations limiting DRV/r re-
sponse occurred in less than 10%, and PR mutations 50V, 
54ML and 76V occurred in less than 5% of patients.
 
CONCLUSION
In conclusion, we showed a high frequency of resistance 
mutations to antiretroviral drugs in patients with virologic 
failure on ART in Paraná, from 2002 to 2006. This was more 
important to the NNRTI class compared to other studies. No 
reduction in the prevalence of mutations over the years was 
seen, as described in other countries. Prevalence of muta-
tions and multidrug-resistant viruses needs to be monitored 
in the future in relation to the evolution of HAART.
Hopefully, the diminishing practice of sequential mon-
otherapy and the availability of more effective and better 
tolerated combination regimens, since 2006, will improve 
suppression of viremia, resulting in prevention of acquired 
resistance.
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